Table 4.
Mortality stratified by patient characteristics
| No. of patients, n (%) | No.a | Mortality |
|---|---|---|
| Overall | 83 803 | 307 (0.4) |
| Likely related to rhGH treatmentb | 83 803 | 24 (0.0) |
| Diagnosis of growth disorder | ||
| Idiopathic GHD | 39 298 | 37 (0.1) |
| Neurosecretory dysfunction | 2187 | 4 (0.2) |
| Congenital GHD | 3323 | 24 (0.7) |
| Craniopharyngioma | 1381 | 24 (1.7) |
| Medulloblastoma | 998 | 37 (3.7) |
| Other cranial tumors | 1750 | 44 (2.5) |
| Extracranial malignancy | 940 | 21 (2.2) |
| Idiopathic short stature | 6867 | 2 (0.0) |
| Turner syndrome | 7714 | 14 (0.2) |
| Prader-Willi syndrome | 2338 | 12 (0.5) |
| Other syndromes | 2602 | 17 (0.7) |
| Small for gestational age | 7936 | 7 (0.1) |
| Chronic renal failure | 2399 | 37 (1.5) |
| Other causes | 4070 | 27 (0.7) |
| Sex | ||
| Female | 35 183 | 133 (0.4) |
| Male | 48 620 | 174 (0.4) |
| Duration of rhGH treatment, y | ||
| < 2 | 32 533 | 168 (0.5) |
| ≥ 2 | 51 270 | 139 (0.3) |
| Attained agec, y | ||
| < 5 | 33 (10.8) | |
| 5-<10 | 56 (18.2) | |
| 10-<15 | 98 (31.9) | |
| 15-<20 | 87 (28.3) | |
| ≥ 20 | 33 (10.8) |
Abbreviations: GHD, growth hormone deficiency; rhGH, recombinant human growth hormone.
a
No. was the denominator used to calculate percentages in each row unless noted otherwise.
b
According to investigators’ opinion.
c
Percentages were calculated with the number of total deaths (n = 307) as a denominator.